ArticleScientific reports2025
A novel method of bayesian genetic optimization on automated hyperparameter tuning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinically Deployable Handwriting Biomarkers of Parkinson's Disease via Multiscale Attention and Bayesian-Genetic Optimization.Brain and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper presents a novel approach that integrates Symbolic Genetic Programming (SGP) with Bayesian techniques within a Deep Neural Network (DNN) framework. The primary contribution of this research is the introduction of a Bayesian-based Genetic Algorithm (BayGA), designed to automate the tuning of hyperparameters for stock market prediction. Prior studies have shown that manual hyperparameter tuning can negatively impact prediction accuracy. The proposed BayGA method effectively optimizes critical hyperparameters' tuning, leading to enhanced predictive performance. Experimental results show that the DNN model combined with BayGA outperforms major stock indices, achieving annualized returns exceeding those of the HS300, CSI500, and CSI1000 by 10.06%, 8.62%, and 16.42%, respectively, with Calmar Ratios of 3.83, 2.71, and 6.20. These findings underscore the effectiveness of the proposed BayGA technique in developing robust financial forecasting models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.